IFNA2 and chronic hepatitis B virus infection: Extensive clinical trials on chronic hepatitis B (CHB) treatment in adult patients with low viral load and hepatitis B surface antigen (HBsAg) levels have demonstrated HBsAg loss rates ranging from 30% to 80% with the use of pegylated interferon α (PEG IFNα) therapy.[1,2] In contrast, the management of HBV-infected children presents distinct challenges, as they are more susceptible to developing CHB, which greatly impacts their overall health and growth, garnering widespread attention.